Listed by the USPTO as SCHMITT, MICHAEL J
Tech Center 1600 • Art Units: 1629
This examiner grants 57% of resolved cases
SCHMITT, MICHAEL J has 664 resolved cases in Tech Center 1600 and Art Unit 1629. The allowance rate is 56.9%, the interview lift is 19.9%, and the median time to allowance is 1041 days. The case volume provides a substantial record, with allowance outcomes forming more than half of the resolved matters.
The listed companies are Mirati Therapeutics Inc., Mayo Foundation for Medical Education and Research, and Virginia Polytechnic Institute and State University. The listed firms are CANTOR COLBURN LLP, Casimir Jones, S.C., and COOLEY LLP. The interview lift is a modest additional signal, so practitioners can consider interviews without assuming they substitute for a strong written record. The median duration should inform portfolio timing and client counseling.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18694921 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | Non-Final OA | MIRATI THERAPEUTICS, INC. |
| 18848249 | METHODS AND MATERIALS FOR TREATING PANCREATIC DISEASES AND DISORDERS | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18560282 | COMBINATIONS FOR TREATMENT OF CANCER | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18847164 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18853520 | COMBINATION THERAPY FOR TREATING CANCER | Non-Final OA | AstraZeneca AB |
| 18796015 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | Non-Final OA | Arizona Board of Regents on Behalf of the University of Arizona |
| 18806178 | BI-FUNCTIONAL MOLECULES TO DEGRADE CIRCULATING PROTEINS | Non-Final OA | Yale University |
| 18272486 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR AMELIORATING NONALCOHOLIC FATTY LIVER DISEASE AND RELATED DISEASES OR DISORDERS | Non-Final OA | Thomas Jefferson University |
| 18188943 | Metabolic Markers of Attention Deficit Hyperactivity Disorder | Final Rejection | Laboratory Corporation of America Holdings |
| 18005269 | METHODS OF TREATING PROTEINOPATHIES | Final Rejection | Woolsey Pharmaceuticals, Inc. |
| 17113571 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | Final Rejection | HANMI PHARM. CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy56.9% of resolved applications examined by Michael J Schmitt were allowed (664 resolved cases), compared with 42.4% across Art Unit 1629 over the last five years.
This examiner's interview lift is +19.9 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Michael J Schmitt took 1,041 days on average from filing to allowance.
Michael J Schmitt examines applications in Art Unit 1629 in Tech Center 1600 (Biotechnology & Pharmaceuticals).